Radius

Quote

anonymous said:
Please understand what this company is. They want to sell the company NOW. They will employ CSO sales reps keep expenses down keep capitalization HIGH. All this to be attractive to a suitor. No way anyone at this point beats Prolia or Forteo. Stock is at $50 with no revenue. Take this job only if you are unemployed or desperate. And no one will EVER see "target"
Click to expand...


The Cambridge, MA-based biotech is hoping to beat out competition from Amgen ($AMGN) and its partner UCB for their experimental bone drug romosozumab (a.k.a. romo).

Back in March, romo--an antibody designed to block the protein sclerostin--achieved its Phase III BRIDGE study primary endpoint of increasing bone mineral density of lumbar spine at 12 months, when compared with placebo.

It also hit its secondary endpoints of bone mineral density increase of femoral neck and total hip at 12 months over placebo, and BMD increase of lumbar spine, femoral neck, and total hip at 6 months over placebo.

This came a month after the company posted generally positive results for the med in its FRAME study for women--although analysts were quick to note that the drug didn't perform as well as abaloparatide.

(Last paragraph......HMMMM...Radius =$$$$)
 



anonymous said:
Did you apply via website or right thru recruiter? I see all the jobs posted on the corporate website and wonder if there is any other way to get in. I have sold in this market before and think this will be a great opportunity. Whether it gets bought down the road or not, start ups are always a risk.
Click to expand...

The Cambridge, MA-based biotech is hoping to beat out competition from Amgen ($AMGN) and its partner UCB for their experimental bone drug romosozumab (a.k.a. romo).

Back in March, romo--an antibody designed to block the protein sclerostin--achieved its Phase III BRIDGE study primary endpoint of increasing bone mineral density of lumbar spine at 12 months, when compared with placebo.

It also hit its secondary endpoints of bone mineral density increase of femoral neck and total hip at 12 months over placebo, and BMD increase of lumbar spine, femoral neck, and total hip at 6 months over placebo.

This came a month after the company posted generally positive results for the med in its FRAME study for women--although analysts were quick to note that the drug didn't perform as well as abaloparatide.

(Last paragraph...HMMM...Radius = $$$$)
 

























































Top Bottom
Back
Quote